TEL
AVIV, Israel, Nov. 14,
2024 /PRNewswire/ -- SoniVie Ltd., a
medical device company developing a proprietary renal denervation
system to treat hypertension, announced today the appointment of
Raymond W. Cohen to serve as its
chairman of the board of directors.
Mr. Cohen has served as the chief executive officer and member
of the board of directors of Axonics, Inc., an Irvine, Calif. based global medical technology
company he cofounded in 2013 and took public October 31, 2018. Axonics ranked No. 1 on the
2021 Deloitte Technology Fast 500™ and the 2022 Financial Times
ranking of the fastest growing companies in the Americas.
Cohen is retiring from Axonics following the close of its
$3.7 billion sale to Boston
Scientific Corporation (NYSE: BSX).
Prior to Axonics, Cohen was the CEO of Vessix Vascular, Inc.
(privately held) which developed a catheter based renal denervation
system that was acquired by BSX in late 2012.
Tomaso Zambelli, CEO of SoniVie,
said "We look forward to benefiting from Mr. Cohen's broad
experience in growing Medtech companies and moreover his expertise
in renal denervation as we execute our PMA study for US FDA
approval and make plans to commercialize our product."
About Raymond W. Cohen
An accredited public company director with over 40 years of
experience in the life sciences industry, Cohen also serves as an
independent director of Kestra Medical Technologies, Inc.,
(privately held) a commercial stage company manufacturing and
marketing a wearable defibrillator product for patients at
temporary risk of cardiac arrest.
Cohen recently received the 2024 MedTech MVP Award and was
also named Businessperson of the Year by the Orange County Business
Journal. In 2021, Mr. Cohen received a lifetime achievement award
from SoCal Bio for his four decades of work in medical technology.
In late 2020, Mr. Cohen was named as Entrepreneur of the Year by
Ernst & Young for the Pacific Southwest United States.
About SoniVie Ltd.
SoniVie has developed TIVUS™ (Therapeutic Intra-Vascular
Ultrasound System) which employs high-frequency non-focused
ultrasound energy to ablate nerves in the renal artery to decrease
blood pressure for patients suffering from hypertension, a
condition impacting millions of people worldwide and substantially
increasing their risk of heart attack, stroke and kidney failure.
In July 2024, the United States FDA
approved the company's PMA study which is now enrolling patients in
the US, Europe and Israel. The "THRIVE" study is an
international, multicenter, randomized, double blind,
sham-controlled study, designed to demonstrate the safety and
effectiveness of the TIVUS™ System in hypertensive
subjects who are off anti-hypertensive medications one month prior
to the procedure until 2 months post procedure. Unblinding will be
performed 6 months post procedure. SoniVie has operations in
Israel, US and Europe.
For more information, please go to www.sonivie.com
PR Contact:
Tomaso Zambelli, CEO
Sonivie Ltd.
tomaso@sonivie.com
View original
content:https://www.prnewswire.co.uk/news-releases/sonivie-ltd-appoints-veteran-medtech-executive-raymond-w-cohen-as-chairman-of-its-board-of-directors-302307758.html